Orphelia Pharma provides update on the regulatory submission of KIZFIZO® with the European Medicines Agency
Orphelia to seek re-examination following CHMP negative opinion for the treatment of relapsed or refractory high-risk neuroblastoma
initiative Octalfa
Engagés pour l'innovation et la santé
